Inhibikase Therapeutics Inc (IKT) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Inhibikase Therapeutics Inc   (NASDAQ: IKT)

Inhibikase Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Inhibikase Therapeutics Inc in the second quarter 2026?
Inhibikase Therapeutics Inc recorded a cumulative net loss of $-61 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -42.8%.

Within the Biotechnology & Pharmaceuticals industry 43 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 2803 to 3137.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 91.53 % 95.52 % 82.26 % - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -61 -51 -48 -48 -42
Return On Equity (TTM) -42.8 % -41.31 % -46.9 % -57.15 % -63.82 %
IKT's Total Ranking # 3137 # 2803 # 2886 # #
Equity (TTM) in Millions 153 168 173 73 80
Seq. Equity Change -8.53 % -3.06 % 137.18 % -8.94 % -6.62 %
Seq. Net Income Change - - - - -

Back to IKT Management Effectiveness >> IKT's 5 Years Annual ROE >> Compare IKT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 44
Sector # 376
Overall # 3137

Return On Equity Statistics
High Average Low
-41.29 %
-91.82 %
-350.62 %
(Mar 31 2022)   (Sep 30 2024)





IKT Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 173 95 11 21 38
Y / Y Equity Change 82.26 % 764.16 % -47.81 % -45.24 % -
Net Income in Millions -48 -28 -19 -18 -15
Y / Y Net Income Change - - - - -
Return On Equity -27.91 % -29.01 % -173.34 % -85.83 % -38.49 %

Back to IKT Management Effectiveness >> IKT's 5 Years Annual ROE >> Compare IKT ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IKT's' Return on Equity at Yahoo Finance
IKT's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IKT's Competitors
Subscribers only: Roe for Inhibikase Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for IKT's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-04T17:23:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.